Driving BioMedical Innovation and Advancing Regulatory Science through Public-Private Partnerships with the U.S. Food and Drug Administration
Featuring Remarks from U.S. FDA Acting Commissioner Stephen Ostroff, M.D. and other distinguished speakers and panelists
October 26 – 27, 2015
United Therapeutics Headquarters
1110 Spring Street
Silver Spring, Maryland, USA
The Johns Hopkins University’s new personal protective suit for frontline health care workers in Ebola outbreaks was honored Monday as one of 10 finalists in the Social Good category of Fast Company’s 2015 Innovation by Design Awards.
The suit, intended for use in future Ebola outbreaks like the 2014 epidemic that killed thousands in West Africa, has elements to keep the wearer more comfortable than existing suits, reduce the risk of coming in contact with the virus and protect against other infectious diseases.
Plans to expand MedImmune’s Frederick manufacturing plant will move forward with financial support from Frederick County after the County Council approved an agreement with tax credits and other economic incentives for the biotechnology firm Tuesday night.
In a 6-1 vote, the Frederick County Council approved the county’s $3.8 million contribution to a $6.8 million conditional loan for MedImmune’s expansion and an agreement guaranteeing the AstraZeneca-owned firm certain tax credits and access to specific county resources over the next decade.
On Tuesday, Rare Genomics Institute (RG), announced that it is launching ten separate crowdfunding campaigns to help patients with rare diseases pinpoint the causes of their illnesses. All amounts raised will go towards exome sequencing, which is a method of partial genome sequencing to find the genetic causes of diseases.
This effort is part of Amplify Hope, initiated by RG to determine the most effective crowdfunding programs and measure their effect on scientific education. Amplify Hope is a new RG study funded by the John Templeton Foundation that provides crowdfunding training to rare disease families and tracks the overall reach and scientific impact to help rare disease patients.
Google Capital has invested $32.5 million in Oscar, a health insurance startup, The Wall Street Journal reports.
The new funding values Oscar, which had in April raised $145 million at a $1.5 billion valuation, at $1.75 billion.
Are you an entrepreneur with or know someone who is? Apply today for the opportunity to make your pitch!
Application deadline September 21.
Apply for a chance to record your 3-minute investor pitch in a mobile video studio on the Startup Maryland bus Montgomery County on September 30.
At each event, 20 entrepreneurs will pitch their companies and network with the business community. Pitches are seen online by VC, angel investors and voted on by fans around Maryland! Fan favorite finalists will present at the TEDCO Entrepreneur Expo on November 17.
The Product Development and Management Association (PDMA), the premier global advocate for product development and management professionals, announced today that it has awarded the 2015 Outstanding Corporate Innovator (OCI) Award to BD (Becton, Dickinson and Company) BDX, +0.68%
BD’s focus on innovation has provided a framework to integrate the business, make acquisitions and coordinate actions vertically, from the top through operating levels of the company.
Join more than 400 of the region’s business and government leaders for the Economic Alliance of Greater Baltimore’s Annual Meeting, November 4, 2015 at the Hilton Baltimore.
While Maryland is known for its history and culture, food and beautiful landscape, this year’s annual meeting will celebrate one of the region’s greatest assets – the people – as they tell their stories. The program will recognize the region’s growing companies and those who make our community a world-class market in which to live, work, learn and invest.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe. The company will showcase the results of the Early Feasibility Study, including a 100 % procedural success rate, over 850 total implant days and echocardiographic data on the first two patients with trace MR during their six-month follow up visit, at the upcoming 2015 Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA on October 12, 2015.
Looks like San Diego life sciences and tech investment firm Avalon Ventures is in the midst of compiling its eleventh fund, looking to raise $300 million.
Fund XI, according to an SEC filing, has raised $103.5 million of the proposed $300 million from 26 investors.
